Literature DB >> 29061336

Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study.

A M W Efsen1, A Schultze2, R F Miller3, A Panteleev4, A Skrahin5, D N Podlekareva6, J M Miro7, E Girardi8, H Furrer9, M H Losso10, J Toibaro10, J A Caylà11, A Mocroft2, J D Lundgren6, F A Post12, O Kirk6.   

Abstract

OBJECTIVES: Mortality among HIV patients with tuberculosis (TB) remains high in Eastern Europe (EE), but details of TB and HIV management remain scarce.
METHODS: In this prospective study, we describe the TB treatment regimens of patients with multi-drug resistant (MDR) TB and use of antiretroviral therapy (ART).
RESULTS: A total of 105 HIV-positive patients had MDR-TB (including 33 with extensive drug resistance) and 130 pan-susceptible TB. Adequate initial TB treatment was provided for 8% of patients with MDR-TB compared with 80% of those with pan-susceptible TB. By twelve months, an estimated 57.3% (95%CI 41.5-74.1) of MDR-TB patients had started adequate treatment. While 67% received ART, HIV-RNA suppression was demonstrated in only 23%.
CONCLUSIONS: Our results show that internationally recommended MDR-TB treatment regimens were infrequently used and that ART use and viral suppression was well below the target of 90%, reflecting the challenging patient population and the environment in which health care is provided. Urgent improvement of management of patients with TB/HIV in EE, in particular for those with MDR-TB, is needed and includes widespread access to rapid TB diagnostics, better access to and use of second-line TB drugs, timely ART initiation with viral load monitoring, and integration of TB/HIV care.
Copyright © 2017 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Eastern Europe; HIV; MDR-TB; Tuberculosis

Mesh:

Substances:

Year:  2017        PMID: 29061336      PMCID: PMC6293190          DOI: 10.1016/j.jinf.2017.10.007

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  34 in total

1.  Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey.

Authors:  Gunar Günther; Gabriela B Gomez; Christoph Lange; Stephan Rupert; Frank van Leth
Journal:  Eur Respir J       Date:  2014-11-13       Impact factor: 16.671

2.  Beyond multidrug-resistant tuberculosis in Europe: a TBNET study.

Authors:  G Günther; F van Leth; N Altet; M Dedicoat; R Duarte; G Gualano; H Kunst; I Muylle; V Spinu; S Tiberi; P Viiklepp; C Lange
Journal:  Int J Tuberc Lung Dis       Date:  2015-12       Impact factor: 2.373

Review 3.  Treatment outcomes for HIV and MDR-TB co-infected adults and children: systematic review and meta-analysis.

Authors:  P Isaakidis; E C Casas; M Das; X Tseretopoulou; E E Ntzani; N Ford
Journal:  Int J Tuberc Lung Dis       Date:  2015-08       Impact factor: 2.373

4.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

Authors:  Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton
Journal:  N Engl J Med       Date:  2015-07-20       Impact factor: 91.245

Review 5.  Tuberculosis treatment and management--an update on treatment regimens, trials, new drugs, and adjunct therapies.

Authors:  Alimuddin Zumla; Jeremiah Chakaya; Rosella Centis; Lia D'Ambrosio; Peter Mwaba; Matthew Bates; Nathan Kapata; Thomas Nyirenda; Duncan Chanda; Sayoki Mfinanga; Michael Hoelscher; Markus Maeurer; Giovanni Battista Migliori
Journal:  Lancet Respir Med       Date:  2015-03-09       Impact factor: 30.700

6.  Short- and long-term mortality and causes of death in HIV/tuberculosis patients in Europe.

Authors:  Daria N Podlekareva; Alexander M Panteleev; Daniel Grint; Frank A Post; Jose M Miro; Mathias Bruyand; Hansjakob Furrer; Niels Obel; Enrico Girardi; Anna Vasilenko; Marcelo H Losso; Alejandro Arenas-Pinto; Joan Caylá; Aza Rakhmanova; Indra Zeltina; Anne Marie Werlinrud; Jens D Lundgren; Amanda Mocroft; Ole Kirk
Journal:  Eur Respir J       Date:  2013-06-13       Impact factor: 16.671

7.  High Treatment Success Rates Among HIV-Infected Multidrug-Resistant Tuberculosis Patients After Expansion of Antiretroviral Therapy in Botswana, 2006-2013.

Authors:  Sanghyuk S Shin; Chawangwa Modongo; Rosanna Boyd; Cynthia Caiphus; Lesego Kuate; Botshelo Kgwaadira; Nicola M Zetola
Journal:  J Acquir Immune Defic Syndr       Date:  2017-01-01       Impact factor: 3.771

8.  Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk.

Authors:  Alena Skrahina; Henadz Hurevich; Aksana Zalutskaya; Evgeni Sahalchyk; Andrei Astrauko; Wayne van Gemert; Sven Hoffner; Valiantsin Rusovich; Matteo Zignol
Journal:  Eur Respir J       Date:  2011-10-17       Impact factor: 16.671

9.  Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013.

Authors:  Amanda Mocroft; Jens Lundgren; Andrea Antinori; Antonella d'Arminio Monforte; Johanna Brännström; Fabrice Bonnet; Norbert Brockmeyer; Jordi Casabona; Antonella Castagna; Dominique Costagliola; Stéphane De Wit; Gerd Fätkenheuer; Hansjakob Furrer; Corinne Jadand; Anne Johnson; Mario Lazanas; Catherine Leport; Santiago Moreno; Christina Mussini; Niels Obel; Frank Post; Peter Reiss; Caroline Sabin; Adriane Skaletz-Rorowski; Ignacio Suarez-Loano; Carlo Torti; Josiane Warszawski; Linda Wittkop; Robert Zangerle; Genevieve Chene; Dorthe Raben; Ole Kirk
Journal:  Euro Surveill       Date:  2015

10.  Evolution and transmission of drug-resistant tuberculosis in a Russian population.

Authors:  Nicola Casali; Vladyslav Nikolayevskyy; Yanina Balabanova; Simon R Harris; Olga Ignatyeva; Irina Kontsevaya; Jukka Corander; Josephine Bryant; Julian Parkhill; Sergey Nejentsev; Rolf D Horstmann; Timothy Brown; Francis Drobniewski
Journal:  Nat Genet       Date:  2014-01-26       Impact factor: 38.330

View more
  5 in total

Review 1.  Chronic Immune Activation in TB/HIV Co-infection.

Authors:  Riti Sharan; Allison N Bucşan; Shashank Ganatra; Mirko Paiardini; Mahesh Mohan; Smriti Mehra; Shabaana A Khader; Deepak Kaushal
Journal:  Trends Microbiol       Date:  2020-04-22       Impact factor: 17.079

2.  Treatment outcomes and antiretroviral uptake in multidrug-resistant tuberculosis and HIV co-infected patients in Sub Saharan Africa: a systematic review and meta-analysis.

Authors:  Elvis Dzelamonyuy Chem; Marie Claire Van Hout; Vivian Hope
Journal:  BMC Infect Dis       Date:  2019-08-16       Impact factor: 3.090

3.  Tuberculosis Drug Susceptibility, Treatment, and Outcomes for Belarusian HIV-Positive Patients with Tuberculosis: Results from a National and International Laboratory.

Authors:  Daria N Podlekareva; Dorte Bek Folkvardsen; Alena Skrahina; Anna Vassilenko; Aliaksandr Skrahin; Henadz Hurevich; Dzmitry Klimuk; Igor Karpov; Jens D Lundgren; Ole Kirk; Troels Lillebaek
Journal:  Tuberc Res Treat       Date:  2021-04-02

4.  Delayed diagnosis of tuberculosis in persons living with HIV in Eastern Europe: associated factors and effect on mortality-a multicentre prospective cohort study.

Authors:  Christian Kraef; Adrian Bentzon; Alexander Panteleev; Alena Skrahina; Natalie Bolokadze; Simona Tetradov; Regina Podlasin; Igor Karpov; Elena Borodulina; Elena Denisova; Inga Azina; Jens Lundgren; Isik Somuncu Johansen; Amanda Mocroft; Daria Podlekareva; Ole Kirk
Journal:  BMC Infect Dis       Date:  2021-10-06       Impact factor: 3.090

5.  High Prevalence of Rifampicin Resistance Associated with Rural Residence and Very Low Bacillary Load among TB/HIV-Coinfected Patients at the National Tuberculosis Treatment Center in Uganda.

Authors:  Joseph Baruch Baluku; Pallen Mugabe; Rose Mulwana; Sylvia Nassozi; Richard Katuramu; William Worodria
Journal:  Biomed Res Int       Date:  2020-07-25       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.